STOCK TITAN

Intensity Therapeutics Inc - INTS STOCK NEWS

Welcome to our dedicated news page for Intensity Therapeutics (Ticker: INTS), a resource for investors and traders seeking the latest updates and insights on Intensity Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Intensity Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Intensity Therapeutics's position in the market.

Rhea-AI Summary
Intensity Therapeutics, Inc. (INTS) to present at the 2024 BIO CEO & Investor Conference. The company focuses on developing immune-based intratumoral cancer therapies. Lewis H. Bender, President and CEO, will give an overview and host meetings on February 26, 2024, in New York.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
conferences
-
Rhea-AI Summary
Intensity Therapeutics, Inc. (INTS) receives FDA 'Study May Proceed' letter for phase 3 protocol in soft tissue sarcoma, plans to initiate study in first half of 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.84%
Tags
clinical trial
-
Rhea-AI Summary
Intensity Therapeutics, Inc. (Nasdaq: INTS) appoints Joseph Talamo as Chief Financial Officer, bringing over 25 years of biotechnology experience. Mr. Talamo will lead financial strategies and reporting to support the company's transition to a late-stage clinical company and the development of proprietary immune-based intratumoral cancer therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
management
Rhea-AI Summary
Intensity Therapeutics, Inc. (INTS) announced safety, tolerability, efficacy, and immune activation data from the Phase 2 INVINCIBLE trial of INT230-6 in early-stage breast cancer patients without chemotherapy at the 2023 San Antonio Breast Cancer Symposium. The trial demonstrated a systemic increase in the median diversity of T-cell repertoire in patients' blood compared to baseline, up to >95% necrosis of a tumor, an increase in CD4 T-cells and NK cells within tumors, and up-regulation of immune pathways expressed by T-cell activation, lymphocyte activation, and inflammatory responses. The treatment had a favorable safety profile and was well tolerated, sparking high patient interest.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
72%
Tags
none
-
Rhea-AI Summary
Intensity Therapeutics, Inc. (Nasdaq: INTS) has been selected for a spotlight oral presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS) on December 8, 2023. Dr. Angel Arnaout will conduct the oral presentation, highlighting the efficacy and immunomodulatory effects of INT230-6 in early-stage breast cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.52%
Tags
none
-
Rhea-AI Summary
Intensity Therapeutics, Inc. (INTS) presented positive Phase 1/2 clinical data for INT230-6 at the Connective Tissue Oncology Society, demonstrating a 93% disease control rate and survival extension of nearly 15 months in patients with refractory soft tissue sarcoma. The company also received Orphan Drug Designation for INT230-6 and closed an upsized IPO for $20.2 million in net proceeds. They are on track to file an IND for Phase 3 study of INT230-6 in soft tissue sarcoma and report additional Phase 2 INVICIBLE study results for presurgical breast cancer by end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
earnings
Rhea-AI Summary
Intensity Therapeutics announces positive safety and efficacy data from Phase 1/2 clinical trial of INT230-6 in patients with sarcomas. The monotherapy showed a disease control rate of 93% and extended survival in refractory soft tissue sarcoma subjects by nearly 15 months. INT230-6 was well tolerated with 90% of adverse events being grade 1 or 2.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
none
-
Rhea-AI Summary
Intensity Therapeutics receives orphan-drug designation for soft tissue sarcoma treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.79%
Tags
clinical trial
-
Rhea-AI Summary
Intensity Therapeutics, Inc. to present company overview at H.C. Wainwright 25th Annual Global Investment Conference on September 11.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.6%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
earnings
Intensity Therapeutics Inc

Nasdaq:INTS

INTS Rankings

INTS Stock Data

54.70M
7.99M
16.03%
3.74%
0.73%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Westport

About INTS

intensity therapeutics is a connecticut based biopharmaceutical company whose mission is to create safer and more efficacious chemotherapy treatments. intensity therapeutics is a preclinical, in vivo stage company seeking investors interested in helping to advance the company’s technology and products.